AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 208 filers reported holding AMICUS THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is 0.13 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,379,923 | -69.2% | 360,191 | -68.2% | 0.01% | -66.7% |
| Q2 2023 | $14,216,990 | -22.4% | 1,131,926 | -31.5% | 0.02% | -25.0% |
| Q1 2023 | $18,316,211 | -32.8% | 1,651,597 | -26.0% | 0.02% | -33.3% |
| Q4 2022 | $27,268,898 | -10.0% | 2,233,325 | -23.1% | 0.03% | -16.7% |
| Q3 2022 | $30,312,000 | -4.9% | 2,903,496 | -2.2% | 0.04% | -2.7% |
| Q2 2022 | $31,884,000 | +10.6% | 2,968,736 | -2.5% | 0.04% | +37.0% |
| Q1 2022 | $28,831,000 | -9.7% | 3,044,438 | +10.1% | 0.03% | +3.8% |
| Q4 2021 | $31,939,000 | +52.6% | 2,765,296 | +26.2% | 0.03% | +36.8% |
| Q3 2021 | $20,934,000 | -26.6% | 2,192,017 | -25.9% | 0.02% | -24.0% |
| Q2 2021 | $28,516,000 | -34.6% | 2,958,147 | -33.0% | 0.02% | -40.5% |
| Q1 2021 | $43,620,000 | -73.3% | 4,414,976 | -37.6% | 0.04% | -71.2% |
| Q4 2020 | $163,468,000 | +57.6% | 7,079,596 | -3.6% | 0.15% | +37.7% |
| Q3 2020 | $103,701,000 | -2.4% | 7,344,264 | +4.2% | 0.11% | -16.5% |
| Q2 2020 | $106,285,000 | +106.7% | 7,048,049 | +26.6% | 0.13% | +58.8% |
| Q1 2020 | $51,428,000 | +38.0% | 5,565,739 | +45.5% | 0.08% | +86.0% |
| Q4 2019 | $37,266,000 | +66.4% | 3,826,041 | +37.0% | 0.04% | +53.6% |
| Q3 2019 | $22,391,000 | -16.5% | 2,791,844 | +30.0% | 0.03% | -15.2% |
| Q2 2019 | $26,800,000 | +96.9% | 2,147,403 | +114.6% | 0.03% | +83.3% |
| Q1 2019 | $13,609,000 | +59.4% | 1,000,626 | +12.3% | 0.02% | +50.0% |
| Q4 2018 | $8,536,000 | -70.6% | 890,980 | -62.9% | 0.01% | -65.7% |
| Q3 2018 | $29,024,000 | -50.1% | 2,400,674 | -35.6% | 0.04% | -53.9% |
| Q2 2018 | $58,185,000 | -12.5% | 3,725,044 | -15.7% | 0.08% | -15.6% |
| Q1 2018 | $66,473,000 | +88.1% | 4,419,779 | +79.9% | 0.09% | +83.7% |
| Q4 2017 | $35,345,000 | -48.0% | 2,456,213 | -45.5% | 0.05% | -52.9% |
| Q3 2017 | $67,943,000 | +65.8% | 4,505,500 | +10.7% | 0.10% | +52.9% |
| Q2 2017 | $40,988,000 | +60.5% | 4,070,295 | +13.6% | 0.07% | +51.1% |
| Q1 2017 | $25,539,000 | +120.5% | 3,581,938 | +53.7% | 0.04% | +125.0% |
| Q4 2016 | $11,583,000 | -31.9% | 2,330,599 | +1.4% | 0.02% | -33.3% |
| Q3 2016 | $17,013,000 | +12.3% | 2,299,071 | -17.2% | 0.03% | +7.1% |
| Q2 2016 | $15,155,000 | -38.2% | 2,775,593 | -4.4% | 0.03% | -36.4% |
| Q1 2016 | $24,535,000 | -26.2% | 2,903,472 | -15.2% | 0.04% | -10.2% |
| Q4 2015 | $33,227,000 | +70.3% | 3,425,496 | +145.6% | 0.05% | +69.0% |
| Q3 2015 | $19,509,000 | -15.5% | 1,394,515 | -14.5% | 0.03% | -14.7% |
| Q2 2015 | $23,075,000 | -17.5% | 1,630,724 | -36.5% | 0.03% | -20.9% |
| Q1 2015 | $27,954,000 | +9.9% | 2,569,326 | -15.9% | 0.04% | +30.3% |
| Q4 2014 | $25,427,000 | +183.8% | 3,056,164 | +103.0% | 0.03% | +175.0% |
| Q3 2014 | $8,959,000 | +359.0% | 1,505,732 | +157.6% | 0.01% | +300.0% |
| Q2 2014 | $1,952,000 | +42.7% | 584,582 | -11.5% | 0.00% | +50.0% |
| Q1 2014 | $1,368,000 | -4.1% | 660,790 | +8.9% | 0.00% | 0.0% |
| Q4 2013 | $1,426,000 | +46.4% | 607,048 | +44.6% | 0.00% | 0.0% |
| Q3 2013 | $974,000 | +12.7% | 419,693 | +13.2% | 0.00% | 0.0% |
| Q2 2013 | $864,000 | – | 370,861 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |